Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03687736 · ClinicalTrials.gov registry record · Phase 4
Subject Satisfaction With AbobutulinumtoxinA Treatment
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT03687736 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 120 participants.
The verdict
NCT03687736, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
An interventional Phase 4 study to assess subject satisfaction with abobotulinumtoxinA treatment.
Interventions
- BIOLOGICAL AbobotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2018-10-02 |
| Est. Completion | 2019-12-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03687736
The ClinicalTrials.gov registry entry for NCT03687736 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AbobotulinumtoxinA is the first listed.
NCT03687736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03687736 about?
NCT03687736 is a clinical study titled "Subject Satisfaction With AbobutulinumtoxinA Treatment". An interventional Phase 4 study to assess subject satisfaction with abobotulinumtoxinA treatment.
What is the current status of trial NCT03687736?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2018-10-02. Estimated completion is 2019-12-04.
What interventions are being tested in trial NCT03687736?
The interventions under investigation include: AbobotulinumtoxinA (BIOLOGICAL).
Who is sponsoring clinical trial NCT03687736?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.